ストックスクリーナーアプリを入手
8.33
23.96%
1.61
プレマーケット:
6.53
-1.80
-21.61%
Immuneering Corp (IMRX) 最新ニュース
IMRX: Atebumetanib plus chemo showed 64% 12-month survival in pancreatic cancer, nearly double standard care - TradingView — Track All Markets
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer - Seeking Alpha
Immuneering reports 64% survival rate in pancreatic cancer trial - Investing.com
Immuneering stock falls after reporting survival data for pancreatic cancer drug - Investing.com
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data - TipRanks
Immuneering reports 64% survival rate in pancreatic cancer trial By Investing.com - Investing.com Canada
Immuneering Corp Announces Interim Data from Phase 2a Trial - TradingView — Track All Markets
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - The Manila Times
Immuneering reports 64% survival rate at 12 months for pancreatic cancer drug - StreetInsider
Immuneering signals fiscal strategy with atebimetinib trial progress - Traders Union
Retail Trends: Will Immuneering Corporation stock see insider buyingCEO Change & Detailed Earnings Play Strategies - moha.gov.vn
All you need to know about Immuneering (IMRX) rating upgrade to buy - MSN
Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 - Seeking Alpha
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy - Yahoo Finance
Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19% - Sahm
Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP - TipRanks
Immuneering Prepares To Share 12-Month Survival Data In Pancreatic Cancer Trial - Nasdaq
Immuneering to provide 12-month survival data for pancreatic cancer drug - Investing.com
Immuneering to provide 12-month survival data for pancreatic cancer drug By Investing.com - Investing.com South Africa
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 - The Manila Times
Wall Street Zen Downgrades Immuneering (NASDAQ:IMRX) to Sell - MarketBeat
Can Immuneering Corporation stock outperform in 2025 bull marketWeekly Trend Report & Long-Term Growth Plans - Улправда
Immuneering on track to dose first patient in pancreatic cancer trial in 2026 - MSN
Pancreatic cancer treatment atebimetinib set for Phase 3 trial - Rare Cancer News
Is Immuneering Corporation stock attractive for income investorsJuly 2025 Update & Stepwise Trade Signal Guides - Улправда
Why Immuneering Corporation stock attracts global investorsGlobal Markets & Accurate Buy Signal Notifications - Улправда
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA - The Manila Times
Immuneering to begin Phase 3 trial of pancreatic cancer drug mid-2026 - Investing.com Australia
Immuneering To Initiate Phase 3 Atebimetinib Trial In Pancreatic Cancer In Mid-2026 - Nasdaq
Immuneering stock rises after FDA and EMA align on Phase 3 trial design By Investing.com - Investing.com South Africa
Immuneering stock rises after FDA and EMA align on Phase 3 trial design - Investing.com
Global trial to test drug combo for first-line pancreatic cancer patients - Stock Titan
Immuneering to be added to the Nasdaq Biotechnology Index - TipRanks
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
Immuneering (Nasdaq: IMRX) to be added to Nasdaq Biotechnology Index on Dec. 22 - Stock Titan
Analyst Confidence Buoys Immuneering’s Clinical Prospects - AD HOC NEWS
Immuneering Corporation (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Sahm
Top investors say Immuneering Corp (IMRX) ticks everything they need - setenews.com
You Should Read This Analysis Before Investing in Immuneering Corp (NASDAQ:IMRX) - uspostnews.com
This trade activity should not be overlooked: Immuneering Corp (IMRX) - setenews.com
Immuneering (IMRX) Stock Analysis Report | Financials & Insights - Benzinga
Will Immuneering Corporation stock see insider buying2025 Earnings Surprises & Stock Timing and Entry Methods - moha.gov.vn
We Think Immuneering (NASDAQ:IMRX) Can Afford To Drive Business Growth - Yahoo Finance
Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? - Yahoo Finance
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Immuneering Corporation (IMRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
A new trading data show Immuneering Corp (IMRX) is showing positive returns. - Setenews
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth - simplywall.st
Combining machine learning predictions for Immuneering Corporation2025 Technical Overview & Technical Pattern Based Signals - newser.com
Best data tools to analyze Immuneering Corporation stockTrend Reversal & Stepwise Trade Execution Plans - newser.com
How Immuneering Corporation stock compares to growth peersLong Setup & Reliable Breakout Stock Forecasts - newser.com
Is Immuneering Corporation stock poised for growthBear Alert & Community Trade Idea Sharing - newser.com
Does Immuneering Corporation qualify in momentum factor screeningMarket Growth Review & Step-by-Step Trade Execution Guides - newser.com
Can Immuneering Corporation stock reach $100 price targetEntry Point & Long-Term Safe Investment Plans - newser.com
28.63%
大文字化:
|
ボリューム (24 時間):